Emd Serono Research & Development Institute, Inc.

This study is testing a two-drug combination (avelumab and lenvatinib) in children with aggressive brain tumors that have returned or progressed after prior treatment. The first part aims to find a safe dose, while the second part will see if the combination can slow tumor growth…

This study tests whether adding different drug combinations to avelumab helps control advanced bladder cancer longer after initial chemotherapy. It involves 256 adults whose cancer hasn't worsened after standard treatment. Researchers will compare how long different drug combinat…

This early-stage trial is testing new combinations of experimental cancer drugs in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to find safe doses and understand how the drugs work in the body. Researchers will also look for…

This study tested whether the drug tepotinib could control advanced lung cancer in people with specific genetic changes in their tumors. Researchers enrolled 337 adults with advanced non-small cell lung cancer that had either METex14 skipping alterations or MET amplification. The…

This early-stage study is testing a new cancer drug called M9466, both alone and in combination with other therapies, in 141 people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check if the drug is safe and how the body proce…

This is a first-in-human, early-stage study to find a safe dose and understand how the body processes a new cancer drug called tuvusertib. It is testing the drug alone and in combination with another cancer drug, niraparib, in about 161 people with advanced solid tumors that have…

This study is testing a new two-drug combination for people with a specific type of advanced lung cancer that has gotten worse after standard treatments. The goal is to see if the combination can shrink tumors and control the cancer. Researchers will also closely monitor the safe…

This study tested whether combining two targeted drugs (tepotinib and osimertinib) could help control advanced non-small cell lung cancer that had developed resistance to osimertinib alone. It enrolled 140 adults whose cancer had a specific genetic change called MET amplification…

This study is testing two new drug combinations for women with advanced ovarian cancer whose tumors grew while on a common type of maintenance therapy called a PARP inhibitor. It aims to see if adding a new drug called tuvusertib to either niraparib or lartesertib can shrink tumo…

This study follows cancer patients who previously received the immunotherapy drug avelumab in earlier clinical trials. Researchers are tracking long-term safety, side effects, and survival outcomes in about 205 participants with various solid tumors. The goal is to gather extende…